The estimated Net Worth of Eli Samaha is at least $77 million dollars as of 7 August 2024. Eli Samaha owns over 999,800 units of Theravance Biopharma Inc stock worth over $77,040,315 and over the last 3 years Eli sold TBPH stock worth over $0.
Eli has made over 7 trades of the Theravance Biopharma Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Eli bought 999,800 units of TBPH stock worth $7,798,440 on 7 August 2024.
The largest trade Eli's ever made was buying 2,633,000 units of Theravance Biopharma Inc stock on 28 December 2022 worth over $15,666,350. On average, Eli trades about 759,667 units every 120 days since 2022. As of 7 August 2024 Eli still owns at least 9,511,150 units of Theravance Biopharma Inc stock.
You can see the complete history of Eli Samaha stock trades at the bottom of the page.
Eli's mailing address filed with the SEC is 150 EAST 58TH ST, STE 1403, NEW YORK, NY, 10155.
Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva, et Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Theravance Biopharma Inc executives and other stock owners filed with the SEC include: